Susac syndrome is a rare acquired autoimmune microangiopathy of the brain, retina, and inner ear. The core disease mechanism is immune-mediated injury of small-vessel endothelium, producing the clinical triad of central nervous system dysfunction, branch retinal artery occlusions, and sensorineural hearing impairment.
Ask a research question about Susac Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Susac Syndrome
creation_date: "2026-05-07T02:04:03Z"
updated_date: "2026-05-16T15:18:07Z"
description: >-
Susac syndrome is a rare acquired autoimmune microangiopathy of the brain,
retina, and inner ear. The core disease mechanism is immune-mediated injury
of small-vessel endothelium, producing the clinical triad of central nervous
system dysfunction, branch retinal artery occlusions, and sensorineural
hearing impairment.
category: Autoimmune
disease_term:
preferred_term: Susac syndrome
term:
id: MONDO:0019390
label: Susac syndrome
mappings:
mondo_mappings:
- term:
id: MONDO:0019390
label: Susac syndrome
mapping_predicate: skos:exactMatch
mapping_source: Orphanet ORPHA:838
mapping_justification: >-
Orphanet ORPHA:838 lists MONDO:0019390 as an exact cross-reference for
Susac syndrome.
external_assertions:
- name: Orphanet Susac syndrome disease record
source: Orphanet
assertion_type: structured_disease_record
external_id: ORPHA:838
url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=838
description: >-
Orphanet's ORPHA:838 record provides the Susac syndrome definition,
retinocochleocerebral vasculopathy synonym, all-ages onset, HPO phenotype
table, and exact MONDO mapping used in this entry.
evidence:
- reference: ORPHA:838
reference_title: Susac syndrome
supports: SUPPORT
evidence_source: OTHER
snippet: "MONDO:0019390 | Exact"
explanation: Orphanet maps ORPHA:838 exactly to the MONDO term used by this entry.
parents:
- Autoimmune Disorder
- Neurological Disorder
- Eye disorder
definitions:
- name: Orphanet Susac syndrome definition
definition_type: OTHER
description: >-
Rare autoimmune-mediated microvascular occlusive disease involving the
brain, retina, and inner ear, clinically characterized by CNS dysfunction,
branch retinal artery occlusions, and sensorineural hearing loss.
evidence:
- reference: ORPHA:838
reference_title: Susac syndrome
supports: SUPPORT
evidence_source: OTHER
snippet: >-
A rare systemic or rheumatologic disease characterized by the triad of central nervous system (CNS) dysfunction, branch retinal artery occlusions (BRAOs) and sensorineural hearing loss (SNHL) due to autoimmune-mediated occlusions of microvessels in the brain, retina, and inner ear.
explanation: >-
Orphanet defines Susac syndrome by the CNS, retinal, and inner-ear triad
caused by autoimmune-mediated microvascular occlusion.
prevalence:
- population: Adults in Austria
percentage: 0.148 per 100,000 five-year period prevalence; 0.024 per 100,000 annual incidence
evidence:
- reference: PMID:27788613
reference_title: "Susac's syndrome: clinical course and epidemiology in a Central European population."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Minimum five-year period prevalence of the disease is 0.148/100,000 (95% confidence interval (CI) 0.071-0.272), annual incidence is 0.024/100,000 (95% CI 0.010-0.047).
explanation: >-
This nationwide Austrian survey provides population-based prevalence and
incidence estimates for adult Susac syndrome.
progression:
- phase: Active relapsing period
notes: >-
Susac syndrome can be monophasic, polycyclic, or chronically active. The
full clinical triad is often incomplete at onset, so repeat retina and
inner-ear assessment is needed during the active disease period.
evidence:
- reference: PMID:37608221
reference_title: "Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Clinical course can be monophasic, polycyclic or chronic continuous.
explanation: >-
The long-term observational series summarizes recognized clinical course
patterns.
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The full triad may not be present at diagnosis but should be sought repeatedly.
explanation: >-
The review supports repeated evaluation for all triad domains because the
complete triad may emerge over time.
- phase: Long-term morbidity
notes: >-
Cognitive and functional morbidity can persist despite improvement during
follow-up, especially after severe cerebral involvement.
evidence:
- reference: PMID:39693597
reference_title: "Clinical Characterization and Prognostic Risk Factors of Susac Syndrome: A Retrospective Multicenter Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Approximately 50% of patients resumed employment while 25% did not return to work.
explanation: >-
The multicenter follow-up cohort documents persistent functional impact
in a substantial subset.
- phase: Systematic-review outcome profile
notes: >-
A 2025 systematic review of 435 published patients found heterogeneous
recovery across neurologic, ophthalmologic, and audiovestibular domains,
with relapse in a minority and uncommon mortality during available
follow-up.
evidence:
- reference: PMID:40715894
reference_title: "Susac Syndrome: A Systematic Review and Survival Analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In a subgroup of 123 patients with available follow-up data (median duration: 12 months), 82.1% (n = 101) remained stable with controlled disease, 12.2% (n = 15) experienced a relapse, and 5.7% (n = 7) died.
explanation: >-
The systematic review provides quantitative follow-up outcomes supporting
relapse and mortality context.
pathophysiology:
- name: Immune-mediated microvascular endotheliopathy
description: >-
Susac syndrome is centered on immune-mediated injury of small-vessel
endothelium in the brain, retina, and inner ear, producing occlusive
microangiopathy rather than primary demyelination.
locations:
- preferred_term: brain
term:
id: UBERON:0000955
label: brain
- preferred_term: retina
term:
id: UBERON:0000966
label: retina
- preferred_term: cochlea
term:
id: UBERON:0001844
label: cochlea
cell_types:
- preferred_term: small-vessel endothelial cell
term:
id: CL:0000071
label: blood vessel endothelial cell
biological_processes:
- preferred_term: immune response
modifier: ABNORMAL
term:
id: GO:0006955
label: immune response
- preferred_term: inflammatory response
modifier: INCREASED
term:
id: GO:0006954
label: inflammatory response
downstream:
- target: CD8 T-cell endothelial injury
description: Cytotoxic T-cell adhesion and effector polarization injure microvascular endothelium.
evidence:
- reference: PMID:31852955
reference_title: "CD8(+) T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Our study identifies CD8+ T-cell-mediated endotheliopathy as a key disease mechanism in SuS and highlights therapeutic opportunities.
explanation: >-
This directly supports CD8 T-cell endothelial injury as a downstream
mechanism of the disease-level microangiopathy.
- target: Retinal arteriolar occlusion
description: Occlusive microangiopathy affects retinal branch arterioles.
evidence:
- reference: ORPHA:838
reference_title: Susac syndrome
supports: SUPPORT
evidence_source: OTHER
snippet: >-
A rare systemic or rheumatologic disease characterized by the triad of central nervous system (CNS) dysfunction, branch retinal artery occlusions (BRAOs) and sensorineural hearing loss (SNHL) due to autoimmune-mediated occlusions of microvessels in the brain, retina, and inner ear.
explanation: >-
Orphanet links autoimmune microvascular occlusion to branch retinal
artery occlusions.
- target: Central nervous system ischemic injury
description: Occlusive microangiopathy produces multifocal brain ischemic lesions.
evidence:
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
subacute encephalopathy with unusual headache and pseudo-psychiatric features associated with multifocal ischemic white matter, grey matter nuclei and specifically corpus callosum lesions along with leptomeningeal enhancement on brain MRI
explanation: >-
The review links Susac CNS manifestations to multifocal ischemic brain
lesions.
evidence:
- reference: PMID:37608221
reference_title: "Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Susac syndrome is a likely autoimmune microangiopathy affecting the brain, retina and inner ear.
explanation: >-
This supports autoimmune microangiopathy affecting the three core organs
as the disease-level mechanism.
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Susac syndrome is a rare disease characterized by an inflammatory microangiopathy limited to the brain, eye, and ear vessels.
explanation: >-
The scoping review independently frames Susac syndrome as an inflammatory
microangiopathy of the same organ triad.
- name: CD8 T-cell endothelial injury
description: >-
Activated cytotoxic CD8-positive T cells adhere to CNS microvessels and
polarize cytotoxic granules toward endothelial targets, supporting a
proximal T-cell-mediated injury mechanism.
cell_types:
- preferred_term: CD8-positive alpha-beta T cell
term:
id: CL:0000625
label: CD8-positive, alpha-beta T cell
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
biological_processes:
- preferred_term: leukocyte cell-cell adhesion
modifier: INCREASED
term:
id: GO:0007159
label: leukocyte cell-cell adhesion
- preferred_term: cellular defense response
modifier: INCREASED
term:
id: GO:0006968
label: cellular defense response
downstream:
- target: Central nervous system ischemic injury
description: Endothelial injury and microhemorrhages contribute to brain tissue damage.
evidence:
- reference: PMID:31852955
reference_title: "CD8(+) T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Our study identifies CD8+ T-cell-mediated endotheliopathy as a key disease mechanism in SuS and highlights therapeutic opportunities.
explanation: >-
The mechanistic study supports CD8 T-cell endotheliopathy as a proximal
injury mechanism feeding CNS tissue injury.
evidence:
- reference: PMID:31852955
reference_title: "CD8(+) T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
By investigating immune cells from the blood, cerebrospinal fluid, and CNS of SuS patients, we demonstrate oligoclonal expansion of terminally differentiated activated cytotoxic CD8+ T cells (CTLs).
explanation: >-
Patient immune profiling supports expansion of activated cytotoxic CD8 T
cells.
- reference: PMID:31852955
reference_title: "CD8(+) T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Our study identifies CD8+ T-cell-mediated endotheliopathy as a key disease mechanism in SuS and highlights therapeutic opportunities.
explanation: >-
The mechanistic study directly identifies CD8 T-cell-mediated
endotheliopathy as a key mechanism.
- name: Humoral microvascular autoimmunity
description: >-
A subset of patients has anti-endothelial cell antibodies, including
complement-activating IgG1, suggesting parallel or amplifying humoral
autoimmunity against the microvasculature.
cell_types:
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
- preferred_term: plasma cell
term:
id: CL:0000786
label: plasma cell
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
biological_processes:
- preferred_term: adaptive immune response
modifier: ABNORMAL
term:
id: GO:0002250
label: adaptive immune response
- preferred_term: complement activation
modifier: INCREASED
term:
id: GO:0006956
label: complement activation
downstream:
- target: Immune-mediated microvascular endotheliopathy
description: Humoral autoimmunity may contribute to endothelial injury in a subset of patients.
evidence:
- reference: PMID:24606999
reference_title: "Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In all seropositive cases, AECA belonged to the complement-activating IgG1 subclass.
explanation: >-
Complement-activating anti-endothelial antibodies support a humoral
route into immune-mediated endotheliopathy in seropositive patients.
evidence:
- reference: PMID:24606999
reference_title: "Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Recently, a role for anti-endothelial cell antibodies (AECA) in SuS has been proposed.
explanation: >-
The multicenter serology study frames AECA as a candidate mechanism.
- reference: PMID:24606999
reference_title: "Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In all seropositive cases, AECA belonged to the complement-activating IgG1 subclass.
explanation: >-
The antibody subclass finding supports complement-capable humoral
microvascular injury in seropositive patients.
- name: Central nervous system ischemic injury
description: >-
Microangiopathic vascular injury produces multifocal brain lesions,
especially corpus callosum and peri-callosal lesions, leading to
encephalopathy, headache, cognitive dysfunction, and focal deficits.
locations:
- preferred_term: brain
term:
id: UBERON:0000955
label: brain
- preferred_term: corpus callosum
term:
id: UBERON:0002336
label: corpus callosum
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
- preferred_term: oligodendrocyte
term:
id: CL:0000128
label: oligodendrocyte
biological_processes:
- preferred_term: apoptotic process
modifier: INCREASED
term:
id: GO:0006915
label: apoptotic process
downstream:
- target: Encephalopathy
description: Cerebral lesions produce encephalopathy and neurocognitive symptoms.
evidence:
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
subacute encephalopathy with unusual headache and pseudo-psychiatric features associated with multifocal ischemic white matter, grey matter nuclei and specifically corpus callosum lesions along with leptomeningeal enhancement on brain MRI
explanation: >-
The review ties encephalopathy to multifocal ischemic brain lesions in
Susac syndrome.
- target: Cognitive impairment
description: Cerebral involvement commonly affects executive function and recall.
evidence:
- reference: PMID:38954275
reference_title: "The neurocognitive and neuropsychiatric manifestations of Susac syndrome: a brief review of the literature and future directions."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Existing literature indicates that cognitive deficits range in severity from subtle to profound.
explanation: >-
This review directly supports cognitive impairment as a downstream CNS
manifestation.
- target: Neuropsychiatric manifestations
description: Cerebral involvement can include psychiatric or behavioral manifestations.
evidence:
- reference: PMID:38954275
reference_title: "The neurocognitive and neuropsychiatric manifestations of Susac syndrome: a brief review of the literature and future directions."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Psychiatric manifestations may be absent or may include anxiety, mood disorders or psychosis.
explanation: >-
The review supports neuropsychiatric symptoms as a less frequent
downstream CNS manifestation.
evidence:
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
subacute encephalopathy with unusual headache and pseudo-psychiatric features associated with multifocal ischemic white matter, grey matter nuclei and specifically corpus callosum lesions along with leptomeningeal enhancement on brain MRI
explanation: >-
The review links the CNS phenotype to multifocal ischemic brain lesions,
including corpus callosum involvement.
- name: Retinal arteriolar occlusion
description: >-
Occlusion of retinal branch arterioles causes retinal ischemia, scotomas,
and visual field defects; fluorescein angiography may show arterial wall
hyperfluorescence even when symptoms are subtle.
locations:
- preferred_term: retina
term:
id: UBERON:0000966
label: retina
cell_types:
- preferred_term: retinal blood vessel endothelial cell
term:
id: CL:0000071
label: blood vessel endothelial cell
downstream:
- target: Branch Retinal Artery Occlusion
description: Branch retinal artery occlusions are the defining retinal manifestation.
evidence:
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
ophthalmological involvement that may be pauci-symptomatic, with bilateral occlusions of the branches of the central artery of the retina at fundoscopy and arterial wall hyperfluorescence on fluorescein angiography
explanation: >-
The review directly supports branch retinal arterial occlusion as the
defining retinal lesion.
- target: Scotoma
description: Retinal ischemia can produce localized visual field loss.
evidence:
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
ophthalmological involvement that may be pauci-symptomatic, with bilateral occlusions of the branches of the central artery of the retina at fundoscopy and arterial wall hyperfluorescence on fluorescein angiography
explanation: >-
Branch retinal artery occlusion supports localized ischemic visual
field defects such as scotoma.
evidence:
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
ophthalmological involvement that may be pauci-symptomatic, with bilateral occlusions of the branches of the central artery of the retina at fundoscopy and arterial wall hyperfluorescence on fluorescein angiography
explanation: >-
The review supports branch retinal artery occlusion and arterial wall
hyperfluorescence as core retinal findings.
- name: Cochleovestibular ischemic injury
description: >-
Microvascular injury of the cochlea and vestibular apparatus produces
sensorineural hearing impairment, tinnitus, vertigo, and imbalance.
locations:
- preferred_term: cochlea
term:
id: UBERON:0001844
label: cochlea
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
downstream:
- target: Sensorineural Hearing Impairment
description: Cochlear ischemic injury leads to sensorineural hearing impairment.
evidence:
- reference: PMID:39379650
reference_title: "Phenotyping vestibulocochlear manifestations in Susac syndrome: a cohort study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Fifteen patients had objectified predominant low- to midfrequency sensorineural hearing loss and 8 out of 18 patients showed abnormalities on vestibular testing, most frequently vestibular evoked myogenic potential-abnormalities, indicating otolith dysfunction.
explanation: >-
The 2025 cohort supports sensorineural hearing loss as an objectively
measured cochleovestibular downstream manifestation.
- target: Vertigo
description: Vestibular involvement can produce vertigo or imbalance.
evidence:
- reference: PMID:39379650
reference_title: "Phenotyping vestibulocochlear manifestations in Susac syndrome: a cohort study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
All 21 patients experienced some form of audiovestibular complaints during the disease course, with vertigo and instability being most frequently reported, followed by hearing loss, tinnitus and aural fullness.
explanation: >-
The 2025 cohort directly supports vertigo and instability as common
vestibular downstream manifestations.
evidence:
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
cochleo-vestibular damage with neurosensorial hearing loss predominating on low frequencies.
explanation: >-
The review supports cochleovestibular involvement and the characteristic
low-frequency sensorineural hearing loss pattern.
phenotypes:
- category: Neurologic
name: Encephalopathy
description: >-
Encephalopathy is one arm of the classic clinical triad and may present
with confusion, cognitive dysfunction, headache, behavioral change, or focal
neurologic symptoms.
phenotype_term:
preferred_term: Encephalopathy
term:
id: HP:0001298
label: Encephalopathy
evidence:
- reference: PMID:39693597
reference_title: "Clinical Characterization and Prognostic Risk Factors of Susac Syndrome: A Retrospective Multicenter Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Susac syndrome (SuS) is a rare disorder characterized by encephalopathy, branch retinal artery occlusion, and sensorineural hearing loss, often accompanied by vertigo.
explanation: >-
This multicenter cohort states the core triad and directly supports
encephalopathy as a defining phenotype.
- category: Neurologic
name: Cognitive impairment
description: >-
Cognitive deficits can range from subtle to profound, with frequent
involvement of executive function and short-term recall.
phenotype_term:
preferred_term: Cognitive impairment
term:
id: HP:0100543
label: Cognitive impairment
evidence:
- reference: PMID:38954275
reference_title: "The neurocognitive and neuropsychiatric manifestations of Susac syndrome: a brief review of the literature and future directions."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Executive function and short-term recall are affected frequently.
explanation: >-
The neurocognitive review supports cognitive impairment as a frequent
manifestation.
- category: Neurologic
name: Neuropsychiatric manifestations
description: >-
Psychiatric symptoms may occur during Susac syndrome, including anxiety,
mood disorder symptoms, or psychosis, although attribution can be
complicated by treatment effects.
phenotype_term:
preferred_term: Atypical behavior
term:
id: HP:0000708
label: Atypical behavior
evidence:
- reference: PMID:38954275
reference_title: "The neurocognitive and neuropsychiatric manifestations of Susac syndrome: a brief review of the literature and future directions."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Psychiatric manifestations may be absent or may include anxiety, mood disorders or psychosis.
explanation: >-
The dedicated neurocognitive and neuropsychiatric review supports
psychiatric manifestations as a disease domain.
- category: Neurologic
name: Headache
description: Headache may accompany subacute encephalopathy and CNS involvement.
phenotype_term:
preferred_term: Headache
term:
id: HP:0002315
label: Headache
evidence:
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
subacute encephalopathy with unusual headache and pseudo-psychiatric features associated with multifocal ischemic white matter, grey matter nuclei and specifically corpus callosum lesions along with leptomeningeal enhancement on brain MRI
explanation: >-
The scoping review includes unusual headache in the CNS diagnostic domain.
- category: Ophthalmologic
name: Branch Retinal Artery Occlusion
description: >-
Branch retinal artery occlusion is the defining ocular manifestation and
may be symptomatic or detected only by ophthalmic testing.
phenotype_term:
preferred_term: Branch retinal artery occlusion
term:
id: HP:0020161
label: Branch retinal artery occlusion
evidence:
- reference: PMID:39693597
reference_title: "Clinical Characterization and Prognostic Risk Factors of Susac Syndrome: A Retrospective Multicenter Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Susac syndrome (SuS) is a rare disorder characterized by encephalopathy, branch retinal artery occlusion, and sensorineural hearing loss, often accompanied by vertigo.
explanation: >-
This directly lists branch retinal artery occlusion as a core feature of
Susac syndrome.
- category: Ophthalmologic
name: Scotoma
description: >-
Retinal branch ischemia can cause focal visual field loss perceived as a
scotoma.
phenotype_term:
preferred_term: Scotoma
term:
id: HP:0000575
label: Scotoma
evidence:
- reference: PMID:24606999
reference_title: "Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Susac syndrome (SuS) is a rare disorder thought to be caused by autoimmune-mediated occlusions of microvessels in the brain, retina and inner ear leading to central nervous system (CNS) dysfunction, visual disturbances due to branch retinal artery occlusions (BRAO), and hearing deficits.
explanation: >-
The snippet supports visual disturbances due to BRAO; scotoma is modeled
as one clinically specific form of visual field disturbance.
- category: Auditory
name: Sensorineural Hearing Impairment
description: >-
Sensorineural hearing impairment is a defining inner-ear manifestation and
may involve low frequencies, although high-frequency loss does not exclude
the diagnosis.
phenotype_term:
preferred_term: Sensorineural hearing impairment
term:
id: HP:0000407
label: Sensorineural hearing impairment
evidence:
- reference: PMID:39693597
reference_title: "Clinical Characterization and Prognostic Risk Factors of Susac Syndrome: A Retrospective Multicenter Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
At disease onset, hearing loss excluding low frequencies occurred in 46.7%.
explanation: >-
The cohort documents hearing loss at onset and notes that non-low-frequency
hearing loss does not exclude Susac syndrome.
- category: Auditory
name: Tinnitus
description: Tinnitus may accompany cochleovestibular involvement.
phenotype_term:
preferred_term: Tinnitus
term:
id: HP:0000360
label: Tinnitus
evidence:
- reference: PMID:27788613
reference_title: "Susac's syndrome: clinical course and epidemiology in a Central European population."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
7 presented with BRAO and 5 had hearing loss or tinnitus at the beginning of the disease.
explanation: >-
This population-based cohort directly reports tinnitus or hearing loss at
the beginning of Susac syndrome.
- category: Neurologic
name: Vertigo
description: Vertigo can occur with vestibulocochlear involvement.
phenotype_term:
preferred_term: Vertigo
term:
id: HP:0002321
label: Vertigo
evidence:
- reference: PMID:39693597
reference_title: "Clinical Characterization and Prognostic Risk Factors of Susac Syndrome: A Retrospective Multicenter Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Susac syndrome (SuS) is a rare disorder characterized by encephalopathy, branch retinal artery occlusion, and sensorineural hearing loss, often accompanied by vertigo.
explanation: >-
The multicenter cohort directly notes vertigo as an accompanying feature.
diagnosis:
- name: Triad-based multimodal diagnostic evaluation
description: >-
Diagnosis requires deliberate evaluation of CNS, retinal, and
cochleovestibular domains, because the complete triad may be absent at
first presentation.
diagnosis_term:
preferred_term: clinical assessment
term:
id: MAXO:0000487
label: clinical assessment
results: >-
Compatible CNS dysfunction, branch retinal artery occlusion or arterial
wall hyperfluorescence, and sensorineural hearing loss support Susac
syndrome.
evidence:
- reference: PMID:37608221
reference_title: "Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Diagnosis is based on the presence of the clinical triad of central nervous system dysfunction, branch retinal artery occlusions and sensorineural hearing loss.
explanation: >-
The observational update states the clinical diagnostic triad.
- name: Brain MRI
description: >-
Brain MRI supports diagnosis by identifying typical callosal and
peri-callosal lesions, often with multifocal ischemic lesions and possible
leptomeningeal enhancement.
diagnosis_term:
preferred_term: magnetic resonance imaging procedure
term:
id: MAXO:0000424
label: magnetic resonance imaging procedure
results: Callosal and peri-callosal lesions support the CNS arm of Susac syndrome.
evidence:
- reference: PMID:37608221
reference_title: "Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Typical MRI findings of callosal and peri-callosal lesions may assist in diagnosis.
explanation: >-
The long-term observational update supports MRI as a diagnostic tool and
identifies characteristic lesion locations.
- name: Retinal fluorescein angiography
description: >-
Fluorescein angiography is used to identify branch retinal artery
occlusions and arterial wall hyperfluorescence, including clinically subtle
retinal involvement.
diagnosis_term:
preferred_term: fluorescein angiography
term:
id: MAXO:0035003
label: fluorescein angiography
results: >-
Branch retinal artery occlusion or arterial wall hyperfluorescence supports
the ocular arm of Susac syndrome.
evidence:
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
ophthalmological involvement that may be pauci-symptomatic, with bilateral occlusions of the branches of the central artery of the retina at fundoscopy and arterial wall hyperfluorescence on fluorescein angiography
explanation: >-
The review supports fluorescein angiography for detecting characteristic
retinal arterial involvement.
- name: Audiometry
description: >-
Audiometric testing documents sensorineural hearing loss and supports the
cochleovestibular diagnostic domain.
diagnosis_term:
preferred_term: audiometric test
term:
id: NCIT:C38036
label: Audiometric Test
results: Sensorineural hearing impairment supports cochleovestibular Susac syndrome involvement.
evidence:
- reference: PMID:32878610
reference_title: "Increased incidence of Susac syndrome: a case series study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
All patients underwent brain MRI, fluorescein angiography and audiometry.
explanation: >-
The case series documents audiometry as part of the applied diagnostic
procedure set.
treatments:
- name: High-dose corticosteroids
description: >-
High-dose corticosteroids are commonly used as first-line induction therapy,
especially for active CNS disease, but monotherapy may be insufficient in
severe encephalopathic disease.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: corticosteroid
term:
id: CHEBI:50858
label: corticosteroid
target_mechanisms:
- target: Immune-mediated microvascular endotheliopathy
treatment_effect: MODULATES
description: Corticosteroids aim to suppress active immune-mediated vascular inflammation.
evidence:
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
First-line treatment mostly consists of high dose corticosteroids.
explanation: >-
High-dose corticosteroid use supports immune modulation of active
microvascular inflammation.
evidence:
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
First-line treatment mostly consists of high dose corticosteroids.
explanation: >-
The scoping review supports high-dose corticosteroids as first-line
treatment.
- name: Intravenous immunoglobulin
description: >-
IVIG is used as adjunctive induction, relapse treatment, or maintenance in
refractory or relapsing Susac syndrome.
treatment_term:
preferred_term: intravenous immunoglobulin therapy
term:
id: NCIT:C121331
label: Intravenous Immunoglobulin Therapy
target_mechanisms:
- target: Humoral microvascular autoimmunity
treatment_effect: MODULATES
description: IVIG may modulate humoral and cellular immune injury.
evidence:
- reference: PMID:26715396
reference_title: "Treatment of Susac Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Additional agents, including intravenous immunoglobulins, intravenous cyclophosphamide, or rituximab are often necessary to induce a sustained remission.
explanation: >-
The treatment review supports IVIG as an immune-modulating adjunct for
sustained remission.
evidence:
- reference: PMID:26715396
reference_title: "Treatment of Susac Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Additional agents, including intravenous immunoglobulins, intravenous cyclophosphamide, or rituximab are often necessary to induce a sustained remission.
explanation: >-
This treatment review supports IVIG as an escalation or adjunctive agent
when corticosteroids are insufficient.
- name: Steroid-sparing immunosuppression
description: >-
Steroid-sparing immunosuppressive therapies, including mycophenolate,
cyclophosphamide, azathioprine, and rituximab, are used for relapsing,
refractory, or severe disease.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: mycophenolate
term:
id: CHEBI:62932
label: mycophenolate
- preferred_term: cyclophosphamide
term:
id: CHEBI:4027
label: cyclophosphamide
- preferred_term: azathioprine
term:
id: CHEBI:2948
label: azathioprine
- preferred_term: rituximab
term:
id: NCIT:C1702
label: Rituximab
target_mechanisms:
- target: CD8 T-cell endothelial injury
treatment_effect: MODULATES
description: Immunosuppressive therapy aims to reduce active immune effector injury.
evidence:
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In refractory patients or in case of relapse, immunomodulatory molecules such as intravenous immunoglobulins or immunosuppressive drugs such as mycophenolate mofetil, cyclophosphamide or rituximab should be started.
explanation: >-
Escalation to broad immunomodulatory and immunosuppressive treatment
supports modulation of active cellular immune effector injury.
- target: Humoral microvascular autoimmunity
treatment_effect: MODULATES
description: B-cell-directed or broader immunosuppression may reduce humoral contributions.
evidence:
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In refractory patients or in case of relapse, immunomodulatory molecules such as intravenous immunoglobulins or immunosuppressive drugs such as mycophenolate mofetil, cyclophosphamide or rituximab should be started.
explanation: >-
Rituximab and broader immunosuppression support modulation of humoral
autoimmune contributors in relapsing or refractory disease.
evidence:
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In refractory patients or in case of relapse, immunomodulatory molecules such as intravenous immunoglobulins or immunosuppressive drugs such as mycophenolate mofetil, cyclophosphamide or rituximab should be started.
explanation: >-
The scoping review supports escalation to immunomodulatory or
immunosuppressive agents in relapsing or refractory disease.
- name: Natalizumab
description: >-
Natalizumab has been reported as an adjunctive therapy targeting
alpha-4-integrin-mediated T-cell adhesion in severe Susac syndrome, but the
human evidence is limited to a small treated case subset alongside other
therapy.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: Natalizumab
term:
id: NCIT:C77862
label: Natalizumab
target_mechanisms:
- target: CD8 T-cell endothelial injury
treatment_effect: MODULATES
description: >-
Natalizumab blocks alpha-4-integrin-mediated leukocyte adhesion, aiming
to interrupt CD8 T-cell adhesion to microvascular endothelium.
evidence:
- reference: PMID:31852955
reference_title: "CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
disease severity decreases in four SuS patients treated with natalizumab along with other therapy.
explanation: >-
Natalizumab support is partial because the report involved only four
patients and concomitant therapy.
evidence:
- reference: PMID:31852955
reference_title: "CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
disease severity decreases in four SuS patients treated with natalizumab along with other therapy.
explanation: >-
The mechanistic study reports decreased disease severity in four treated
patients, but treatment was combined with other therapy, so support is
partial.
- name: Aspirin adjunctive therapy
description: >-
Aspirin is described as an adjunctive antiplatelet agent in Susac syndrome,
but published treatment-review evidence explicitly notes that efficacy data
are scant.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: acetylsalicylic acid
term:
id: CHEBI:15365
label: acetylsalicylic acid
target_mechanisms:
- target: Retinal arteriolar occlusion
treatment_effect: MODULATES
description: >-
Aspirin is used adjunctively to address the occlusive microvascular
component, while efficacy evidence remains limited.
evidence:
- reference: PMID:26715396
reference_title: "Treatment of Susac Syndrome."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Aspirin may be used as an adjunctive agent, although evidence showing efficacy is scant.
explanation: >-
Aspirin is an adjunctive antiplatelet approach to the occlusive
microvascular component, but efficacy evidence is limited.
evidence:
- reference: PMID:26715396
reference_title: "Treatment of Susac Syndrome."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Aspirin may be used as an adjunctive agent, although evidence showing efficacy is scant.
explanation: >-
The treatment review supports aspirin use only as an adjunct with limited
efficacy evidence.
clinical_trials:
- name: NCT06881368
phase: NOT_APPLICABLE
status: NOT_RECRUITING
description: >-
CARESS prospective cohort for phenotypic and etiological characterization
of adult Susac syndrome, designed to collect defined cases with at least
two triad signs after exclusion of key mimics.
target_phenotypes:
- preferred_term: Encephalopathy
term:
id: HP:0001298
label: Encephalopathy
- preferred_term: Branch retinal artery occlusion
term:
id: HP:0020161
label: Branch retinal artery occlusion
- preferred_term: Sensorineural hearing impairment
term:
id: HP:0000407
label: Sensorineural hearing impairment
evidence:
- reference: clinicaltrials:NCT06881368
reference_title: Phenotypic and Etiological Characterization of Susac Syndrome
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
SUSAC's Syndrome (SS) is characterized by the clinical triad of encephalopathy, hearing loss, and retinal artery branch occlusions.
explanation: >-
The trial record supports a current prospective cohort focused on the
Susac clinical triad.
- name: NCT01481662
phase: NOT_APPLICABLE
status: UNKNOWN
description: >-
French retrospective and prospective cohort designed to characterize
epidemiological, clinical, etiological, diagnostic, imaging, treatment, and
biomarker features of Susac syndrome.
target_phenotypes:
- preferred_term: Encephalopathy
term:
id: HP:0001298
label: Encephalopathy
- preferred_term: Branch retinal artery occlusion
term:
id: HP:0020161
label: Branch retinal artery occlusion
- preferred_term: Sensorineural hearing impairment
term:
id: HP:0000407
label: Sensorineural hearing impairment
evidence:
- reference: clinicaltrials:NCT01481662
reference_title: "Epidemiological, Clinical and Etiological Features of SUSAC's Syndrome (RETINOCOCHLEOCEREBRAL Vasculopathy)"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The exhaustive and systematic analysis of each case will help to better define different aspects of the disease such as the incidence and prevalence, the clinical presentation, the diagnostic modalities and the impact of treatments.
explanation: >-
The trial record supports systematic cohort collection across
epidemiology, clinical presentation, diagnosis, and treatment impact.
- name: NCT01273792
phase: NOT_APPLICABLE
status: UNKNOWN
description: >-
Biomarker study aiming to identify relevant biomarkers and clarify Susac
syndrome pathogenesis.
target_phenotypes:
- preferred_term: Encephalopathy
term:
id: HP:0001298
label: Encephalopathy
evidence:
- reference: clinicaltrials:NCT01273792
reference_title: Investigation of Relevant Biomarkers in Patients With Susac Syndrome
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The aim of this investigation is to identify relevant biomarkers and to elucidate the pathogenesis of Susac syndrome
explanation: >-
The trial record supports biomarker/pathogenesis investigation as a
Susac-specific clinical study.
references:
- reference: DOI:10.1007/s00415-023-11891-z
title: "Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients)."
found_in:
- Susac_Syndrome-deep-research-falcon.md
findings:
- statement: Long-term clinical series supporting the triad, MRI findings, clinical course, and treatment algorithm.
supporting_text: "Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients)."
evidence:
- reference: PMID:37608221
reference_title: "Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Susac syndrome is a likely autoimmune microangiopathy affecting the brain, retina and inner ear.
explanation: >-
Deep research cited this clinical series for Susac triad and mechanism
context.
- reference: DOI:10.1016/j.autrev.2022.103097
title: "Susac syndrome: A scoping review."
found_in:
- Susac_Syndrome-deep-research-falcon.md
findings:
- statement: Scoping review supporting inflammatory microangiopathy, diagnostic domains, relapsing course, and immunosuppressive treatment.
supporting_text: "Susac syndrome: A scoping review."
evidence:
- reference: PMID:35413469
reference_title: "Susac syndrome: A scoping review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Susac syndrome is a rare disease characterized by an inflammatory microangiopathy limited to the brain, eye, and ear vessels.
explanation: >-
Deep research cited this review for inflammatory microangiopathy and
diagnostic domain context.
- reference: DOI:10.1186/1742-2094-11-46
title: "Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study."
found_in:
- Susac_Syndrome-deep-research-falcon.md
findings:
- statement: Multicenter study supporting anti-endothelial cell antibodies and complement-capable humoral autoimmunity in a subset.
supporting_text: "Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study."
evidence:
- reference: PMID:24606999
reference_title: "Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In all seropositive cases, AECA belonged to the complement-activating IgG1 subclass.
explanation: >-
Deep research cited this multicenter study for humoral autoimmunity in
Susac syndrome.
- reference: DOI:10.1186/s13256-023-03838-9
title: "Use of disease assessment tools to increase the value of case reports on Susac syndrome: two case reports."
found_in:
- Susac_Syndrome-deep-research-falcon.md
findings:
- statement: Case-report source supporting structured disease assessment and monitoring context.
supporting_text: "Use of disease assessment tools to increase the value of case reports on Susac syndrome: two case reports."
evidence:
- reference: DOI:10.1186/s13256-023-03838-9
reference_title: "Use of disease assessment tools to increase the value of case reports on Susac syndrome: two case reports"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
There is a need for disease assessment tools that can help clinicians and patients to more easily, accurately, and uniformly track the clinical course and outcome of Susac syndrome.
explanation: >-
Deep research cited this report for structured assessment and monitoring
context.
- reference: DOI:10.1212/nxi.0000000000200357
title: "Clinical Characterization and Prognostic Risk Factors of Susac Syndrome: A Retrospective Multicenter Study."
found_in:
- Susac_Syndrome-deep-research-falcon.md
findings:
- statement: Multicenter cohort supporting phenotype triad, exacerbation timing, prognosis, and functional outcomes.
supporting_text: "Clinical Characterization and Prognostic Risk Factors of Susac Syndrome: A Retrospective Multicenter Study."
evidence:
- reference: PMID:39693597
reference_title: "Clinical Characterization and Prognostic Risk Factors of Susac Syndrome: A Retrospective Multicenter Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Susac syndrome (SuS) is a rare disorder characterized by encephalopathy, branch retinal artery occlusion, and sensorineural hearing loss, often accompanied by vertigo.
explanation: >-
Deep research cited this multicenter cohort for triad and prognosis
context.
- reference: DOI:10.1038/s41467-019-13593-5
title: "CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome."
found_in:
- Susac_Syndrome-deep-research-falcon.md
findings:
- statement: Mechanistic study supporting CD8 T-cell-mediated endothelial injury and targetability of T-cell adhesion.
supporting_text: "CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome."
evidence:
- reference: PMID:31852955
reference_title: "CD8(+) T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Our study identifies CD8+ T-cell-mediated endotheliopathy as a key disease mechanism in SuS and highlights therapeutic opportunities.
explanation: >-
Deep research cited this mechanistic study for targetable CD8
endotheliopathy.
- reference: DOI:10.1080/00207454.2016.1254631
title: "Susac's syndrome: clinical course and epidemiology in a Central European population."
found_in:
- Susac_Syndrome-deep-research-falcon.md
findings:
- statement: Population-based Austrian study supporting prevalence and incidence estimates.
supporting_text: "Susac's syndrome: clinical course and epidemiology in a Central European population."
evidence:
- reference: PMID:27788613
reference_title: "Susac's syndrome: clinical course and epidemiology in a Central European population."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Minimum five-year period prevalence of the disease is 0.148/100,000 (95% confidence interval (CI) 0.071-0.272), annual incidence is 0.024/100,000 (95% CI 0.010-0.047).
explanation: >-
Deep research cited this population-based study for incidence and
prevalence estimates.
- reference: DOI:10.1186/s12883-020-01892-0
title: "Increased incidence of Susac syndrome: a case series study."
found_in:
- Susac_Syndrome-deep-research-falcon.md
findings:
- statement: Case series supporting multimodal diagnostic procedures and possible post-infectious observations.
supporting_text: "Increased incidence of Susac syndrome: a case series study."
evidence:
- reference: PMID:32878610
reference_title: "Increased incidence of Susac syndrome: a case series study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Infectious serological findings may imply a post infectious mechanism.
explanation: >-
Deep research cited this case series for possible post-infectious
observations and diagnostic context.
- reference: DOI:10.1007/s10072-024-07672-9
title: "The neurocognitive and neuropsychiatric manifestations of Susac syndrome: a brief review of the literature and future directions."
found_in:
- Susac_Syndrome-deep-research-falcon.md
findings:
- statement: Review supporting neurocognitive and neuropsychiatric manifestations.
supporting_text: "The neurocognitive and neuropsychiatric manifestations of Susac syndrome: a brief review of the literature and future directions."
evidence:
- reference: PMID:38954275
reference_title: "The neurocognitive and neuropsychiatric manifestations of Susac syndrome: a brief review of the literature and future directions."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Existing literature indicates that cognitive deficits range in severity from subtle to profound.
explanation: >-
Deep research cited this review for neurocognitive and
neuropsychiatric manifestations.
- reference: DOI:10.3389/fneur.2024.1339438
title: "Case report: Susac syndrome-two ends of the spectrum, single center case reports and review of the literature."
found_in:
- Susac_Syndrome-deep-research-falcon.md
findings:
- statement: Review and case-report source supporting diagnostic challenge, black-blood MRI utility, and treatability with timely intervention.
supporting_text: "Case report: Susac syndrome-two ends of the spectrum, single center case reports and review of the literature."
evidence:
- reference: DOI:10.3389/fneur.2024.1339438
reference_title: "Case report: Susac syndrome-two ends of the spectrum, single center case reports and review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Diagnosing Susac syndrome may be extremely challenging not only due to its rarity, but also due to the variability of its clinical presentation.
explanation: >-
Deep research cited this case-report review for diagnostic challenge and
timely-treatment context.
- reference: DOI:10.1007/s11940-015-0386-x
title: Treatment of Susac Syndrome.
found_in:
- Susac_Syndrome-deep-research-falcon.md
findings:
- statement: Treatment review supporting expert-guided early aggressive immunomodulatory therapy and monitoring.
supporting_text: Treatment of Susac Syndrome.
evidence:
- reference: PMID:26715396
reference_title: "Treatment of Susac Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Additional agents, including intravenous immunoglobulins, intravenous cyclophosphamide, or rituximab are often necessary to induce a sustained remission.
explanation: >-
Deep research cited this treatment review for aggressive
immunomodulatory therapy and monitoring.
- reference: ORPHA:838
title: Susac syndrome
findings:
- statement: >-
Orphanet defines Susac syndrome, lists retinocochleocerebral
vasculopathy as a synonym, maps the disease exactly to MONDO:0019390, and
provides HPO frequencies for headache, corpus-callosum abnormality,
sensorineural hearing impairment, visual loss, confusion, and cognitive
impairment.
supporting_text: >-
A rare systemic or rheumatologic disease characterized by the triad of central nervous system (CNS) dysfunction, branch retinal artery occlusions (BRAOs) and sensorineural hearing loss (SNHL) due to autoimmune-mediated occlusions of microvessels in the brain, retina, and inner ear.
evidence:
- reference: ORPHA:838
reference_title: Susac syndrome
supports: SUPPORT
evidence_source: OTHER
snippet: >-
A rare systemic or rheumatologic disease characterized by the triad of central nervous system (CNS) dysfunction, branch retinal artery occlusions (BRAOs) and sensorineural hearing loss (SNHL) due to autoimmune-mediated occlusions of microvessels in the brain, retina, and inner ear.
explanation: >-
Orphanet provides disease definition, cross-reference, and phenotype
context for Susac syndrome.
- reference: PMID:40715894
title: "Susac Syndrome: A Systematic Review and Survival Analysis."
findings:
- statement: >-
2025 systematic review of 435 published patients supporting quantitative
phenotype frequencies, incomplete triad at onset, relapse, mortality, and
domain-specific recovery outcomes.
supporting_text: >-
A total of 435 patients (males: 32.6%, n = 142), derived from 176 studies, were included in the analysis.
evidence:
- reference: PMID:40715894
reference_title: "Susac Syndrome: A Systematic Review and Survival Analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A total of 435 patients (males: 32.6%, n = 142), derived from 176 studies, were included in the analysis.
explanation: >-
This systematic review provides the largest current published-patient
outcome synthesis identified during the Susac enhancement audit.
- reference: PMID:39379650
title: "Phenotyping vestibulocochlear manifestations in Susac syndrome: a cohort study."
findings:
- statement: >-
2025 cohort supporting detailed audiovestibular phenotyping, low- to
mid-frequency sensorineural hearing loss, vestibular-test abnormalities,
and otolith dysfunction.
supporting_text: >-
Fifteen patients had objectified predominant low- to midfrequency sensorineural hearing loss and 8 out of 18 patients showed abnormalities on vestibular testing, most frequently vestibular evoked myogenic potential-abnormalities, indicating otolith dysfunction.
evidence:
- reference: PMID:39379650
reference_title: "Phenotyping vestibulocochlear manifestations in Susac syndrome: a cohort study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Fifteen patients had objectified predominant low- to midfrequency sensorineural hearing loss and 8 out of 18 patients showed abnormalities on vestibular testing, most frequently vestibular evoked myogenic potential-abnormalities, indicating otolith dysfunction.
explanation: >-
This cohort provides contemporary audiovestibular phenotype evidence.
- reference: DOI:10.1007/s10072-025-08451-w
title: Susac syndrome - different treatment approaches for one disease (analysis of case series)
findings:
- statement: >-
2025 case-series analysis supporting heterogeneous treatment response and
the need for individualized long-term immunosuppression strategies.
supporting_text: >-
The described cases highlight differences in the course of the disease and response to immunosuppressive therapy.
evidence:
- reference: DOI:10.1007/s10072-025-08451-w
reference_title: Susac syndrome - different treatment approaches for one disease (analysis of case series)
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The described cases highlight differences in the course of the disease and response to immunosuppressive therapy.
explanation: >-
This 2025 case series supports heterogeneous treatment response and
individualized treatment planning.
datasets:
Susac syndrome is a rare, immune-mediated, ischemia-producing occlusive microvascular endotheliopathy that affects the brain, retina, and inner ear, producing a characteristic clinical triad of encephalopathy/central nervous system dysfunction, branch retinal artery occlusions (BRAO), and sensorineural hearing loss. (bose2023susacsyndromeneurological pages 1-2, jarius2014clinicalparaclinicaland pages 1-2, bullock2023useofdisease pages 1-2)
Most available evidence is derived from: - Case reports and case series, reflecting rarity (jarius2014clinicalparaclinicaland pages 1-2, bose2023susacsyndromeneurological pages 1-2) - Retrospective cohorts (fuchs2025clinicalcharacterizationand pages 1-2) - Prospective observational cohorts / registries and biomarker studies on ClinicalTrials.gov (NCT01273792 chunk 1, NCT01481662 chunk 1, NCT06881368 chunk 1)
Current evidence supports SuS as a primarily immune-mediated endotheliopathy of small vessels, with converging support for CD8+ cytotoxic T-cell (CTL)–mediated endothelial injury and (in a subset) humoral/complement involvement. (gross2019cd8+tcellmediated pages 1-2, bose2023susacsyndromeneurological pages 1-2, jarius2014clinicalparaclinicaland pages 1-2)
Direct abstract quote (mechanism; primary literature): - Gross et al. (Nature Communications, 2019) report: “CTLs adhere to CNS microvessels … and polarize granzyme B, which most likely results in the observed endothelial cell injury and microhemorrhages” and that “Blocking T-cell adhesion by anti-α4 integrin-intervention ameliorates the disease in the preclinical model.” (gross2019cd8+tcellmediated pages 1-2)
Demographic risk: young adult onset and female predominance are repeatedly observed in cohorts/series. (david2022susacsyndromea pages 1-2, seifertheld2017susacssyndromeclinical pages 6-10)
Possible infectious triggers (limited evidence): In an Israeli series of 7 patients, recent cytomegalovirus (CMV) exposure was “serologically evident in three patients,” and one had a high antistreptolysin titer—interpreted as potentially supporting a post-infectious mechanism (observational association, not proof of causality). (wilfyarkoni2020increasedincidenceof pages 2-3)
No protective genetic or environmental factors were identified in the retrieved evidence.
No gene–environment interactions were identified in the retrieved evidence.
Frequency examples: encephalopathy is part of triad; in one 16-patient series, encephalopathy occurred at some point in most patients but was present at onset in 6/16 (37.5%). (bose2023susacsyndromeneurological pages 1-2)
Retinal involvement: BRAO, arterial wall hyperfluorescence (AWH), visual field defects; may be clinically silent.
In a 16-patient series, objective retinal ischemia was documented in ~11/16. (bose2023susacsyndromeneurological pages 6-8)
Vestibulocochlear involvement: sensorineural hearing loss, tinnitus, vertigo/balance problems.
A 2024 review highlights that cognitive deficits range from subtle to profound, with executive function and short-term recall frequently affected; psychiatric manifestations may include anxiety, mood disorders, or psychosis, and attribution may be confounded by steroid side effects. (koncz2024theneurocognitiveand pages 1-2)
Direct abstract quote (2024 review): “Executive function and short-term recall are affected frequently. Psychiatric manifestations may be absent or may include anxiety, mood disorders or psychosis.” (koncz2024theneurocognitiveand pages 1-2)
Functional impairment is substantial in a subset. In a 20-patient multicenter cohort, ~50% resumed employment while 25% did not return to work. (fuchs2025clinicalcharacterizationand pages 1-2)
No causal genes or pathogenic germline variants were identified in the retrieved evidence; SuS is not established as a monogenic disorder in these sources.
No evidence identified in the retrieved texts.
A current working model is that immune dysregulation causes microvascular endothelial injury and occlusion leading to ischemia in brain/retina/inner ear.
A structured mechanism table (cell types, GO/CL suggestions) is provided below.
| Mechanism component | Evidence summary | Upstream/downstream | Cell types (CL suggestions) | Pathways/GO biological process terms | Key primary sources (PMID if known, else DOI/URL and year) |
|---|---|---|---|---|---|
| Immune-mediated endotheliopathy as initiating lesion | Susac syndrome is consistently described as an immune-mediated occlusive microvascular endotheliopathy affecting precapillary arterioles of the brain, retina, and inner ear, providing the unifying mechanism for the clinical triad. Pathology is centered on small-vessel endothelial injury rather than primary demyelination. (bose2023susacsyndromeneurological pages 1-2, david2022susacsyndromea pages 1-2, fuchs2025clinicalcharacterizationand pages 1-2) | Upstream disease-defining process | Endothelial cell (CL: 0000115); vascular endothelial cell (CL: 0002543) | GO: endothelial cell apoptotic process; blood vessel morphogenesis; regulation of vascular permeability; inflammatory response | Bose et al., J Neurol 2023, https://doi.org/10.1007/s00415-023-11891-z; David et al., Autoimmun Rev 2022, https://doi.org/10.1016/j.autrev.2022.103097; Fuchs et al., Neurol Neuroimmunol Neuroinflamm 2025, https://doi.org/10.1212/NXI.0000000000200357 |
| CD8+ cytotoxic T-cell adhesion to CNS microvessels | In SuS, oligoclonally expanded activated CD8+ CTLs adhere to CNS microvessels and polarize granzyme B toward endothelium, which is proposed to drive endothelial injury and microhemorrhages. CSF/blood immune phenotyping showed increased activated CD8+ cells and reduced intrathecal CD4/CD8 ratio, supporting a cytotoxic T-cell process. (gross2019cd8+tcellmediated pages 1-2, bose2023susacsyndromeneurological pages 5-6) | Upstream to endothelial damage; proximal effector mechanism | CD8-positive, alpha-beta T cell (CL: 0000625); effector memory CD8-positive, alpha-beta T cell (suggested CL family term); endothelial cell (CL: 0000115) | GO: leukocyte cell-cell adhesion; T cell activation; granzyme-mediated apoptotic signaling pathway; cell killing; transendothelial migration | Gross et al., Nat Commun 2019, https://doi.org/10.1038/s41467-019-13593-5; Bose et al., J Neurol 2023, https://doi.org/10.1007/s00415-023-11891-z |
| Targetability of T-cell trafficking / anti-α4 integrin evidence | In a transgenic model recapitulating SuS-like endothelial injury, blocking T-cell adhesion with anti-α4 integrin ameliorated disease; similarly, disease severity decreased in four SuS patients treated with natalizumab along with other therapies. This supports leukocyte adhesion/trafficking as a targetable step. (gross2019cd8+tcellmediated pages 1-2) | Therapeutic interruption of upstream effector step | CD8-positive, alpha-beta T cell (CL: 0000625); endothelial cell (CL: 0000115) | GO: integrin-mediated signaling pathway; leukocyte migration; leukocyte adhesion to vascular endothelial cell | Gross et al., Nat Commun 2019, https://doi.org/10.1038/s41467-019-13593-5 |
| Humoral autoimmunity / AECA subset | Anti-endothelial cell antibodies (AECA) were detected in 25% (5/20) of definite SuS cases, with median titers far higher than controls; titers >1:320 were exclusive to SuS. AECA positivity persisted over time in some patients, but seropositivity did not clearly segregate with severity, suggesting pathogenicity in a subset rather than all cases. (jarius2014clinicalparaclinicaland pages 1-2) | Upstream or parallel contributor to endothelial injury in a subset | B cell (CL: 0000236); plasma cell (CL: 0000786); endothelial cell (CL: 0000115) | GO: immunoglobulin mediated immune response; complement activation, classical pathway; antigen binding | Jarius et al., J Neuroinflammation 2014, https://doi.org/10.1186/1742-2094-11-46 |
| Complement-activating AECA subclass | In all seropositive cases in the international multicenter study, AECA belonged to complement-activating IgG1; many samples also had IgA and 45% had IgM AECA. This supports the plausibility of antibody-mediated complement fixation on endothelium. (jarius2014clinicalparaclinicaland pages 1-2, jarius2014clinicalparaclinicaland pages 8-9) | Upstream/parallel humoral amplification mechanism | B cell (CL: 0000236); plasma cell (CL: 0000786); endothelial cell (CL: 0000115) | GO: complement activation; classical pathway; Fc receptor signaling pathway; humoral immune response | Jarius et al., J Neuroinflammation 2014, https://doi.org/10.1186/1742-2094-11-46 |
| Complement deposition in tissue (C4d) | Brain histology in the 2023 UK series showed C4d immunostaining with complement deposition in capillaries and venules in ~30% of vessels, interpreted as evidence of humoral-mediated microangiopathy. This complements earlier pathology reports linking vascular immune injury to ischemic damage. (bose2023susacsyndromeneurological pages 1-2) | Intermediate amplification step between immune attack and ischemic injury | Endothelial cell (CL: 0000115); perivascular lymphocyte (suggested immune cell term) | GO: complement activation; membrane attack complex assembly; regulation of endothelial cell injury | Bose et al., J Neurol 2023, https://doi.org/10.1007/s00415-023-11891-z |
| Endothelial necrosis and vascular narrowing/occlusion | Histology/autopsy studies show endothelial cell necrosis, perivascular lymphocytic infiltration, vascular narrowing/occlusion, and small-vessel vasculitic change. These lesions mechanistically link immune attack to reduced perfusion in affected organs. (bose2023susacsyndromeneurological pages 1-2, david2022susacsyndromea pages 1-2, cvikova2024casereportsusac pages 1-2) | Intermediate lesion-forming step | Endothelial cell (CL: 0000115); lymphocyte (CL: 0000542); CD8-positive, alpha-beta T cell (CL: 0000625) | GO: endothelial cell death; vasculature development; inflammatory response; regulation of blood circulation | Bose et al., J Neurol 2023, https://doi.org/10.1007/s00415-023-11891-z; Cviková et al., Front Neurol 2024, https://doi.org/10.3389/fneur.2024.1339438 |
| Microinfarcts and microangiopathic ischemic injury | Multiple microinfarcts involving gray matter, white matter, deep nuclei, brainstem, and corpus callosum were found on biopsy/autopsy; these are the tissue-level consequence of occluded microvessels. This explains diffusion-restricted lesions and the characteristic callosal MRI abnormalities. (bose2023susacsyndromeneurological pages 1-2, david2022susacsyndromea pages 1-2, gross2019cd8+tcellmediated pages 1-2) | Downstream tissue injury | Neuron (CL: 0000540); oligodendrocyte (CL: 0000128); astrocyte (CL: 0000127); endothelial cell (CL: 0000115) | GO: response to ischemia; cell death; axon injury response; gliogenesis | Bose et al., J Neurol 2023, https://doi.org/10.1007/s00415-023-11891-z; Gross et al., Nat Commun 2019, https://doi.org/10.1038/s41467-019-13593-5 |
| Brain involvement in the clinical triad | Cerebral microvascular injury produces encephalopathy, headache, focal deficits, cognitive dysfunction, psychiatric/behavioral change, and typical MRI lesions (especially corpus callosum “snowballs,” pericallosal lesions, leptomeningeal enhancement). This is the brain arm of the triad. (bose2023susacsyndromeneurological pages 1-2, david2022susacsyndromea pages 1-2, koncz2024theneurocognitiveand pages 1-2) | Downstream organ-level manifestation | Neuron (CL: 0000540); astrocyte (CL: 0000127); microglial cell (CL: 0000129); endothelial cell (CL: 0000115) | GO: response to ischemia; cognition; regulation of synaptic signaling; neuroinflammatory response | Bose et al., J Neurol 2023, https://doi.org/10.1007/s00415-023-11891-z; Koncz et al., Neurol Sci 2024, https://doi.org/10.1007/s10072-024-07672-9 |
| Retinal involvement in the clinical triad | The same occlusive microangiopathy in retinal arterioles causes BRAO, arterial wall hyperfluorescence, scotomas, and sometimes clinically silent retinal ischemia detectable on FA/OCT. This is the ocular arm of the triad and one of the most actionable diagnostic windows into ongoing microvascular disease. (cvikova2024casereportsusac pages 7-8, fuchs2025clinicalcharacterizationand pages 1-2) | Downstream organ-level manifestation | Retinal vascular endothelial cell (suggest endothelial cell term); retinal ganglion cell (CL suggestion); pericyte (CL suggestion) | GO: retina vasculature development; response to hypoxia; visual perception; blood vessel occlusion | Cviková et al., Front Neurol 2024, https://doi.org/10.3389/fneur.2024.1339438; Fuchs et al., Neurol Neuroimmunol Neuroinflamm 2025, https://doi.org/10.1212/NXI.0000000000200357 |
| Cochlear/vestibular involvement in the clinical triad | Occlusive injury of inner-ear microvessels, especially the apical cochlea, leads to low- to middle-frequency sensorineural hearing loss, tinnitus, and sometimes vertigo/vestibular dysfunction. This is the ear arm of the triad and may be irreversible when infarction is advanced. (cvikova2024casereportsusac pages 7-8, fuchs2025clinicalcharacterizationand pages 1-2) | Downstream organ-level manifestation | Cochlear hair cell (CL suggestion); vestibular hair cell (CL suggestion); endothelial cell (CL: 0000115) | GO: sensory perception of sound; inner ear development; response to ischemia | Cviková et al., Front Neurol 2024, https://doi.org/10.3389/fneur.2024.1339438; Fuchs et al., Neurol Neuroimmunol Neuroinflamm 2025, https://doi.org/10.1212/NXI.0000000000200357 |
| Integrated causal chain | Working model: immune dysregulation → CD8+ CTL adhesion to microvessels ± AECA/complement activation in a subset → endothelial injury/necrosis and vascular narrowing → occlusive microangiopathy and microinfarcts → brain/retina/cochlea ischemia → encephalopathy, BRAO/retinal ischemia, and hearing loss/vertigo. (gross2019cd8+tcellmediated pages 1-2, jarius2014clinicalparaclinicaland pages 1-2, bose2023susacsyndromeneurological pages 1-2, david2022susacsyndromea pages 1-2) | Full upstream-to-downstream disease map | CD8-positive, alpha-beta T cell (CL: 0000625); B cell (CL: 0000236); endothelial cell (CL: 0000115); neuron (CL: 0000540); cochlear hair cell (CL suggestion) | GO: immune effector process; complement activation; endothelial cell death; response to ischemia; sensory perception of sound; visual perception | Gross et al., Nat Commun 2019, https://doi.org/10.1038/s41467-019-13593-5; Jarius et al., J Neuroinflammation 2014, https://doi.org/10.1186/1742-2094-11-46; Bose et al., J Neurol 2023, https://doi.org/10.1007/s00415-023-11891-z; David et al., Autoimmun Rev 2022, https://doi.org/10.1016/j.autrev.2022.103097 |
Table: This table summarizes the current mechanistic model of Susac syndrome, from upstream immune injury to downstream ischemic damage in brain, retina, and cochlea. It is useful for knowledge-base curation because it links causal steps, cell types, ontology suggestions, and primary evidence.
Gross et al. provide mechanistic and translational evidence that blocking α4-integrin–mediated T-cell adhesion can ameliorate disease in a preclinical model and report decreased severity in four treated patients (observational), highlighting leukocyte trafficking as a therapeutic target. (gross2019cd8+tcellmediated pages 1-2)
Not specifically described in the retrieved evidence.
SuS may follow monocyclic/monophasic, polycyclic, or chronic-continuous courses. (bose2023susacsyndromeneurological pages 8-9, vodopivec2016treatmentofsusac pages 1-3)
In a 20-patient cohort, cerebral and inner-ear exacerbations were most common in the first year, whereas retinal exacerbations occurred more frequently mainly within the first 2 years. (fuchs2025clinicalcharacterizationand pages 1-2)
Diagnostic delay is common due to incomplete triad at onset; a UK series reported mean time to diagnosis of 3 months. (bose2023susacsyndromeneurological pages 6-8)
A nationwide Austrian survey (adults >19 years) estimated:
- Annual incidence: 0.024 per 100,000 (95% CI 0.010–0.047)
- Minimum 5-year period prevalence: 0.148 per 100,000 (95% CI 0.071–0.272) (seifertheld2017susacssyndromeclinical pages 6-10)
A structured table of key statistics is provided below.
| Finding/statistic | Value | Population/cohort | Notes | Source (include DOI/URL and year) |
|---|---|---|---|---|
| Annual incidence | 0.024 per 100,000 (95% CI 0.010–0.047) | Adult Susac syndrome patients in Austria; nationwide survey, 8 newly diagnosed over 5 years | Adults >19 years only; minimum annual incidence estimate | Seifert-Held et al., Int J Neurosci 2017, doi:10.1080/00207454.2016.1254631, https://doi.org/10.1080/00207454.2016.1254631 (seifertheld2017susacssyndromeclinical pages 6-10) |
| Minimum 5-year prevalence | 0.148 per 100,000 (95% CI 0.071–0.272) | Adult Susac syndrome patients in Austria; nationwide survey (n=10) | Minimum 5-year period prevalence in adults >19 years | Seifert-Held et al., Int J Neurosci 2017, doi:10.1080/00207454.2016.1254631, https://doi.org/10.1080/00207454.2016.1254631 (seifertheld2017susacssyndromeclinical pages 1-6, seifertheld2017susacssyndromeclinical pages 6-10) |
| Sex ratio | Female:male = 3:1 | UK case series, 16 patients | Mean age 35.6 years (range 18–60) | Bose et al., J Neurol 2023, doi:10.1007/s00415-023-11891-z, https://doi.org/10.1007/s00415-023-11891-z (bose2023susacsyndromeneurological pages 1-2) |
| Mean age at onset / sex ratio | Mean age 38.9 years; female:male = 1.86 | Multicenter retrospective cohort, 20 patients | Mean follow-up 55.9 months | Fuchs et al., Neurol Neuroimmunol Neuroinflamm 2025, doi:10.1212/NXI.0000000000200357, https://doi.org/10.1212/NXI.0000000000200357 (fuchs2025clinicalcharacterizationand pages 1-2) |
| Diagnostic delay | Mean 3 months | UK case series, 16 patients | Delay attributed in part to incomplete/sequential triad | Bose et al., J Neurol 2023, doi:10.1007/s00415-023-11891-z, https://doi.org/10.1007/s00415-023-11891-z (bose2023susacsyndromeneurological pages 6-8) |
| Complete clinical triad at onset | 13% initially | UK case series, 16 patients | Full triad uncommon at first presentation | Bose et al., J Neurol 2023, doi:10.1007/s00415-023-11891-z, https://doi.org/10.1007/s00415-023-11891-z (bose2023susacsyndromeneurological pages 6-8) |
| Complete clinical triad over disease course | 80% eventually | UK case series, 16 patients | Supports repeated reassessment over time | Bose et al., J Neurol 2023, doi:10.1007/s00415-023-11891-z, https://doi.org/10.1007/s00415-023-11891-z (bose2023susacsyndromeneurological pages 6-8) |
| Cognitive improvement during follow-up | 75% improved | Multicenter retrospective cohort, 20 patients | Improvement measured during mean 55.9-month follow-up | Fuchs et al., Neurol Neuroimmunol Neuroinflamm 2025, doi:10.1212/NXI.0000000000200357, https://doi.org/10.1212/NXI.0000000000200357 (fuchs2025clinicalcharacterizationand pages 1-2) |
| Return to work | Approximately 50% resumed employment | Multicenter retrospective cohort, 20 patients | Employment used as a practical long-term outcome | Fuchs et al., Neurol Neuroimmunol Neuroinflamm 2025, doi:10.1212/NXI.0000000000200357, https://doi.org/10.1212/NXI.0000000000200357 (fuchs2025clinicalcharacterizationand pages 1-2) |
| Failure to return to work | 25% did not return to work | Multicenter retrospective cohort, 20 patients | Indicates substantial functional morbidity despite treatment | Fuchs et al., Neurol Neuroimmunol Neuroinflamm 2025, doi:10.1212/NXI.0000000000200357, https://doi.org/10.1212/NXI.0000000000200357 (fuchs2025clinicalcharacterizationand pages 1-2) |
| Serum IgG anti-endothelial cell antibodies (AECA) positivity | 25% (5/20) of definite Susac syndrome patients | International multicenter serologic study; 20 definite SuS patients, 70 controls | Controls: 4.3% (3/70); median titer in SuS 1:3200 | Jarius et al., J Neuroinflammation 2014, doi:10.1186/1742-2094-11-46, https://doi.org/10.1186/1742-2094-11-46 (jarius2014clinicalparaclinicaland pages 1-2) |
| AECA subclass | Complement-activating IgG1 subclass in all seropositive cases | International multicenter serologic study | Supports humoral/complement-mediated contribution in a subset | Jarius et al., J Neuroinflammation 2014, doi:10.1186/1742-2094-11-46, https://doi.org/10.1186/1742-2094-11-46 (jarius2014clinicalparaclinicaland pages 1-2) |
Table: This table summarizes high-yield epidemiology, diagnostic timing, prognosis, and serologic findings for Susac syndrome from major cohort and multicenter studies. It is useful for quickly comparing incidence, demographic patterns, functional outcomes, and AECA-related mechanistic evidence.
A practical widely cited approach is the European Susac Consortium (EuSaC) 2016 criteria, which define brain, retinal, and vestibulocochlear involvement with specific required clinical/imaging findings, yielding definite/probable/possible diagnoses. (cvikova2024casereportsusac pages 7-8, cvikova2024casereportsusac media 1cd8097f)
Modern practice emphasizes multimodal confirmation: - Brain MRI (callosal/pericallosal lesions; “snowballs”) (bose2023susacsyndromeneurological pages 1-2) - Fluorescein angiography (BRAO/AWH) and OCT/SD-OCT (cvikova2024casereportsusac pages 7-8, wilfyarkoni2020increasedincidenceof pages 2-3) - Audiogram ± vestibular testing (cvikova2024casereportsusac pages 7-8, fuchs2025clinicalcharacterizationand pages 1-2) - CSF (typically raised protein; OCB usually absent) (bose2023susacsyndromeneurological pages 1-2, cvikova2024casereportsusac pages 7-8)
A structured diagnostic/workflow table (with ontology suggestions) is provided below.
| Domain | Key tests/findings | Practical notes (what to order/when) | Ontology suggestions (HPO/LOINC/RadLex where applicable) | Key sources (DOI/URL, year) |
|---|---|---|---|---|
| EuSaC diagnostic framework | Definite SuS requires all 3 domains; probable = 2/3; possible = 1/3. Brain: new cognitive/behavioral change and/or focal neurologic symptoms and/or new headache plus typical MRI lesions including at least one corpus callosum “snowball.” Retina: BRAO or arterial wall hyperfluorescence (AWH) on fluorescein angiography, or branch ischemia on fundoscopy/SD-OCT. Vestibulocochlear: new tinnitus and/or hearing loss and/or peripheral vertigo with supportive testing. | In suspected SuS, deliberately evaluate brain + retina + inner ear, even if only one domain is symptomatic. Repeat testing over time because the full triad is often absent initially. | HPO: Encephalopathy; Cognitive impairment; Headache; Branch retinal artery occlusion; Sensorineural hearing impairment; Tinnitus; Vertigo. RadLex: brain MRI; fluorescein angiography; SD-OCT; audiogram. | Front Neurol review summarizing EuSaC 2016 criteria and table image extraction (https://doi.org/10.3389/fneur.2024.1339438, 2024) (cvikova2024casereportsusac pages 7-8, cvikova2024casereportsusac media 1cd8097f) |
| Brain MRI: core diagnostic imaging | Typical MRI: hyperintense multifocal small round lesions, especially central corpus callosum “snowballs”; pericallosal lesions common. Internal capsule “string of pearls” pattern is evocative. | Order brain MRI early in any unexplained encephalopathy/headache/focal deficits when SuS is possible. Sagittal FLAIR/T2 sequences are particularly helpful for callosal lesions. MRI can strongly support diagnosis when triad is incomplete. | RadLex: MRI brain, FLAIR, diffusion-weighted MRI. HPO: Abnormal brain MRI; Corpus callosum lesion. | J Neurol case series/review (https://doi.org/10.1007/s00415-023-11891-z, 2023); Autoimmun Rev scoping review (https://doi.org/10.1016/j.autrev.2022.103097, 2022) (bose2023susacsyndromeneurological pages 1-2, david2022susacsyndromea pages 1-2) |
| Leptomeningeal enhancement | Post-contrast MRI may show multifocal leptomeningeal enhancement; reported in ~23–44% historically, and up to 56–100% in some newer contrast-enhanced FLAIR series. Association of callosal microischemic lesions plus leptomeningeal enhancement is highly suggestive/pathognomonic in context. | If routine MRI is equivocal but suspicion remains high, include contrast-enhanced FLAIR when available. Particularly useful in active cerebral disease and headache-dominant presentations. | RadLex: Contrast-enhanced FLAIR MRI; leptomeningeal enhancement. HPO: Leptomeningeal enhancement; Headache. | Front Neurol review (https://doi.org/10.3389/fneur.2024.1339438, 2024); Autoimmun Rev review (https://doi.org/10.1016/j.autrev.2022.103097, 2022) (cvikova2024casereportsusac pages 7-8, david2022susacsyndromea pages 1-2) |
| Vessel-wall / black-blood MRI | Black-blood high-resolution vessel-wall MRI can show circumferential wall thickening/enhancement and periarterial/periadventitial enhancement, interpreted as inflammatory endothelial injury/vasculopathy. | Consider when standard MRI is nondiagnostic, differential includes CNS vasculitis/MS, or when monitoring suspected ongoing vascular inflammatory activity. Best viewed as an adjunct, not a replacement for standard MRI + retinal/audiologic testing. | RadLex: Vessel wall MRI; black-blood MRI. | Front Neurol review/case report (https://doi.org/10.3389/fneur.2024.1339438, 2024) (cvikova2024casereportsusac pages 1-2, cvikova2024casereportsusac pages 7-8) |
| Retinal fluorescein angiography (FFA/FA) | Hallmark retinal findings: branch retinal artery occlusions (BRAO), arterial wall hyperfluorescence (AWH), and later microaneurysms. BRAOs may be clinically silent; FFA is often diagnostic even when fundus exam is subtle. | Order FA/FFA in all suspected SuS cases, even without visual complaints. Repeat during follow-up/relapse surveillance, since retinal activity may recur and may be more frequent within first 2 years. | HPO: Branch retinal artery occlusion; Scotoma; Visual field defect. RadLex: Fluorescein angiography. | Neurol Neuroimmunol Neuroinflamm cohort (https://doi.org/10.1212/NXI.0000000000200357, 2025); Front Neurol review (https://doi.org/10.3389/fneur.2024.1339438, 2024) (fuchs2025clinicalcharacterizationand pages 1-2, cvikova2024casereportsusac pages 7-8) |
| OCT / SD-OCT | SD-OCT can show characteristic signs of retinal branch ischemia; OCT was used in real-world cohorts to detect acute swelling and chronic ischemic thinning corresponding to BRAO territories. Helpful when fundoscopy is normal/subtle. | Add OCT/SD-OCT alongside FFA, especially if ophthalmic symptoms are absent or minimal. Useful for baseline documentation and longitudinal monitoring of retinal structural damage. | RadLex: Optical coherence tomography; spectral-domain OCT. HPO: Retinal ischemia; Visual field defect. | Front Neurol review (https://doi.org/10.3389/fneur.2024.1339438, 2024); BMC Neurol case series (https://doi.org/10.1186/s12883-020-01892-0, 2020) (cvikova2024casereportsusac pages 7-8, wilfyarkoni2020increasedincidenceof pages 2-3) |
| Audiogram / vestibulocochlear testing | Tonal audiogram typically shows sensorineural hearing loss affecting low-to-middle frequencies, often due to apical cochlear infarction; audiogram becomes abnormal in almost all tested patients. Vestibular testing may support peripheral vertigo. | Order audiogram at baseline in any suspected or confirmed case, even if hearing symptoms are mild. Add vestibular testing (e.g., calorics/VEMP/video head impulse) if vertigo or imbalance is reported. High-frequency loss does not exclude SuS. | HPO: Sensorineural hearing impairment; Tinnitus; Vertigo. LOINC/general: audiogram/hearing assessment. | Front Neurol review (https://doi.org/10.3389/fneur.2024.1339438, 2024); Neurol Neuroimmunol Neuroinflamm cohort (https://doi.org/10.1212/NXI.0000000000200357, 2025) (cvikova2024casereportsusac pages 7-8, fuchs2025clinicalcharacterizationand pages 1-2) |
| CSF profile | Typical CSF pattern is pauci-inflammatory: mild to moderate protein elevation, mild lymphocytic pleocytosis in up to ~45%, and oligoclonal bands/intrathecal IgG synthesis are rare. In one 2023 series, 12/14 had raised protein and OCBs were absent in all 13 tested. | Perform CSF mainly to support diagnosis and exclude mimics (MS, infection, ADEM, vasculitis). SuS CSF usually supports a non-MS inflammatory microangiopathy rather than classic demyelinating disease. | LOINC/general: CSF total protein; CSF white blood cell count; CSF oligoclonal bands. HPO: Elevated CSF protein; CSF pleocytosis. | J Neurol 2023 (https://doi.org/10.1007/s00415-023-11891-z, 2023); Front Neurol 2024 (https://doi.org/10.3389/fneur.2024.1339438, 2024) (bose2023susacsyndromeneurological pages 1-2, cvikova2024casereportsusac pages 7-8) |
| Histopathology / mechanistic adjuncts | Brain pathology shows multiple microinfarcts, endothelial cell necrosis, perivascular lymphocytic infiltration; complement deposition (C4d) seen in a subset (~30% of vessels in one case series). AECA are present in only a subset of patients, so not currently a routine standalone diagnostic biomarker. | Biopsy is not routine; reserve for highly atypical cases or when alternative diagnoses remain strongly suspected. Mechanistic findings support autoimmune endotheliopathy but are not required for bedside diagnosis. | GO: complement activation; leukocyte adhesion; endothelial cell injury. CL: CD8-positive alpha-beta T cell; endothelial cell. | J Neurol 2023 (https://doi.org/10.1007/s00415-023-11891-z, 2023); J Neuroinflammation 2014 (https://doi.org/10.1186/1742-2094-11-46, 2014); Nat Commun 2019 (https://doi.org/10.1038/s41467-019-13593-5, 2019) (bose2023susacsyndromeneurological pages 1-2, jarius2014clinicalparaclinicaland pages 1-2, gross2019cd8+tcellmediated pages 1-2) |
| Real-world diagnostic workflow | Practical workup in contemporary cohorts combines neurology + ophthalmology + otology review with MRI, FFA/OCT, audiogram/vestibular testing, and CSF. Prospective cohorts/registries are using the same multimodal workup plus neurocognitive and disability scales. | In routine care, if SuS is suspected: order brain MRI with contrast, urgent FFA with OCT, audiogram, and CSF; repeat retina/ear testing because domains can emerge sequentially. Natural-history studies are collecting these same tests prospectively, showing these are current real-world implementations rather than experimental-only tools. | HPO: Cognitive impairment; Visual field defect; Sensorineural hearing impairment. RadLex: MRI/FFA/OCT. Functional scales used in cohorts: MoCA, mRS, SF-36, Barthel. | Neurol Neuroimmunol Neuroinflamm 2025 (https://doi.org/10.1212/NXI.0000000000200357, 2025); ClinicalTrials.gov NCT06881368, NCT01481662, NCT01273792 (2010–2025 registry records) (fuchs2025clinicalcharacterizationand pages 1-2, NCT01273792 chunk 1, NCT06881368 chunk 2, NCT01481662 chunk 1, NCT06881368 chunk 1) |
Table: This table summarizes the main diagnostic domains, tests, and real-world workflow for Susac syndrome, including imaging, ophthalmic, audiologic, and CSF findings. It is useful as a knowledge-base-ready quick reference linking practical clinical actions with ontology suggestions and primary sources.
Prospective cohort protocols explicitly exclude key mimics such as multiple sclerosis, CADASIL, mitochondrial disease, CNS tumors, and Lyme disease, reflecting real-world diagnostic workups. (NCT06881368 chunk 2, NCT01481662 chunk 1)
In a multicenter cohort (n=20): - Cognitive function improved in 75% during follow-up. (fuchs2025clinicalcharacterizationand pages 1-2) - ~50% resumed employment; 25% did not return to work, indicating persistent morbidity in a substantial subset. (fuchs2025clinicalcharacterizationand pages 1-2)
Severe cerebral involvement at onset, male sex, and elevated CSF protein were associated with worse prognosis in disability/dependency in one multicenter study. (fuchs2025clinicalcharacterizationand pages 1-2)
There are no randomized controlled trials; treatment is guided by expert consensus, retrospective series, and analogy to other immune-mediated microvascular diseases. (fuchs2025clinicalcharacterizationand pages 1-2, david2022susacsyndromea pages 4-5)
Commonly described regimens include: - High-dose corticosteroids (e.g., IV methylprednisolone induction followed by slow taper) (david2022susacsyndromea pages 4-5, bose2023susacsyndromeneurological pages 1-2) - IVIG as induction/relapse management or adjunct, often used more frequently in relapsing disease (bose2023susacsyndromeneurological pages 1-2, david2022susacsyndromea pages 4-5) - Escalation/maintenance immunosuppression: mycophenolate mofetil, azathioprine, cyclophosphamide, rituximab (david2022susacsyndromea pages 4-5, cvikova2024casereportsusac pages 7-8) - Adjunct antiplatelet therapy is frequently used (e.g., aspirin noted in an Austrian cohort; antiplatelet agents frequently used in reviews). (seifertheld2017susacssyndromeclinical pages 6-10, david2022susacsyndromea pages 4-5)
A 2023 UK series proposed a severity- and response-guided therapeutic algorithm based on long-term management experience, emphasizing early aggressive therapy in severe cases to reduce morbidity/disability. (bose2023susacsyndromeneurological pages 1-2)
No established primary prevention is described in the retrieved evidence. Given rarity and unclear triggers, prevention focuses on: - Secondary/tertiary prevention via early recognition and aggressive treatment to prevent irreversible brain/retinal/cochlear damage. (bose2023susacsyndromeneurological pages 1-2, bullock2023useofdisease pages 1-2)
No naturally occurring SuS analog in non-human species was identified in the retrieved evidence.
A transgenic mouse model recapitulating key features of SuS-like CTL-mediated endotheliopathy was reported in a major mechanistic study and was used to demonstrate benefit of anti-α4 integrin intervention. (gross2019cd8+tcellmediated pages 1-2)
2024 Frontiers review emphasizes black-blood vessel-wall MRI and provides a concise operationalization of EuSaC criteria and updated imaging prevalence ranges. (cvikova2024casereportsusac pages 7-8)
Neuropsychiatric/cognitive phenotype focus (2024):
2024 review highlights gaps in standardized cognitive phenotyping and calls for longitudinal data capture and treatment-outcome correlations in neuropsychiatric domains. (koncz2024theneurocognitiveand pages 1-2)
Real-world research infrastructure (ongoing):
References
(bose2023susacsyndromeneurological pages 1-2): Smriti Bose, Athanasios Papathanasiou, Sameep Karkhanis, Jason P. Appleton, Dominic King, Ruchika Batra, Susan P. Mollan, and Saiju Jacob. Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients). Journal of Neurology, 270:6193-6206, Aug 2023. URL: https://doi.org/10.1007/s00415-023-11891-z, doi:10.1007/s00415-023-11891-z. This article has 28 citations and is from a domain leading peer-reviewed journal.
(david2022susacsyndromea pages 1-2): Clémence David, Karim Sacré, Marie-Cécile Henri-Feugeas, Isabelle Klein, Serge Doan, Fleur Aubart Cohen, Eric Jouvent, and Thomas Papo. Susac syndrome: a scoping review. Autoimmunity Reviews, 21:103097, Jun 2022. URL: https://doi.org/10.1016/j.autrev.2022.103097, doi:10.1016/j.autrev.2022.103097. This article has 55 citations and is from a peer-reviewed journal.
(jarius2014clinicalparaclinicaland pages 1-2): Sven Jarius, Ilka Kleffner, Jan M Dörr, Jaume Sastre-Garriga, Zsolt Illes, Eric Eggenberger, Colin Chalk, Marius Ringelstein, Orhan Aktas, Xavier Montalban, Kai Fechner, Winfried Stöcker, Erich B Ringelstein, Friedemann Paul, and Brigitte Wildemann. Clinical, paraclinical and serological findings in susac syndrome: an international multicenter study. Journal of Neuroinflammation, 11:46, Mar 2014. URL: https://doi.org/10.1186/1742-2094-11-46, doi:10.1186/1742-2094-11-46. This article has 165 citations and is from a peer-reviewed journal.
(bullock2023useofdisease pages 1-2): Danielle R. Bullock, Robert T. Spencer, Richard K. Vehe, Sunil Srivastava, and Robert M. Rennebohm. Use of disease assessment tools to increase the value of case reports on susac syndrome: two case reports. Journal of Medical Case Reports, Apr 2023. URL: https://doi.org/10.1186/s13256-023-03838-9, doi:10.1186/s13256-023-03838-9. This article has 2 citations and is from a peer-reviewed journal.
(fuchs2025clinicalcharacterizationand pages 1-2): Lior Fuchs, Adi Wilf-Yarkoni, Hadar Kolb, Ifat Vigiser, Keren Regev, Dinah Zur, Zohar Habot-Wilner, Yahav Oron, Viktoria Furer, Nitai Shimon, Mark A. Hellmann, Itay Lotan, Eitan Auriel, Robert Rennebohm, Ori Elkayam, and Arnon Karni. Clinical characterization and prognostic risk factors of susac syndrome. Neurology Neuroimmunology & Neuroinflammation, Mar 2025. URL: https://doi.org/10.1212/nxi.0000000000200357, doi:10.1212/nxi.0000000000200357. This article has 5 citations.
(NCT01273792 chunk 1): Jan-Markus Dörr. Investigation of Biomarkers in Susac Syndrome. Charite University, Berlin, Germany. 2010. ClinicalTrials.gov Identifier: NCT01273792
(NCT01481662 chunk 1): Epidemiological, Clinical and Etiological Features of SUSAC's Syndrome. Assistance Publique - Hôpitaux de Paris. 2011. ClinicalTrials.gov Identifier: NCT01481662
(NCT06881368 chunk 1): Phenotypic and Etiological Characterization of Susac Syndrome. Assistance Publique - Hôpitaux de Paris. 2025. ClinicalTrials.gov Identifier: NCT06881368
(gross2019cd8+tcellmediated pages 1-2): Catharina C. Gross, Céline Meyer, Urvashi Bhatia, Lidia Yshii, Ilka Kleffner, Jan Bauer, Anna R. Tröscher, Andreas Schulte-Mecklenbeck, Sebastian Herich, Tilman Schneider-Hohendorf, Henrike Plate, Tanja Kuhlmann, Markus Schwaninger, Wolfgang Brück, Marc Pawlitzki, David-Axel Laplaud, Delphine Loussouarn, John Parratt, Michael Barnett, Michael E. Buckland, Todd A. Hardy, Stephen W. Reddel, Marius Ringelstein, Jan Dörr, Brigitte Wildemann, Markus Kraemer, Hans Lassmann, Romana Höftberger, Eduardo Beltrán, Klaus Dornmair, Nicholas Schwab, Luisa Klotz, Sven G. Meuth, Guillaume Martin-Blondel, Heinz Wiendl, and Roland Liblau. Cd8+ t cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in susac syndrome. Nature Communications, Dec 2019. URL: https://doi.org/10.1038/s41467-019-13593-5, doi:10.1038/s41467-019-13593-5. This article has 150 citations and is from a highest quality peer-reviewed journal.
(seifertheld2017susacssyndromeclinical pages 6-10): Thomas Seifert-Held, Beate J. Langner-Wegscheider, Martina Komposch, Philipp Simschitz, Claudia Franta, Barbara Teuchner, Hans Offenbacher, Ferdinand Otto, Johann Sellner, Helmut Rauschka, and Franz Fazekas. Susac's syndrome: clinical course and epidemiology in a central european population. International Journal of Neuroscience, 127:776-780, Sep 2017. URL: https://doi.org/10.1080/00207454.2016.1254631, doi:10.1080/00207454.2016.1254631. This article has 65 citations and is from a peer-reviewed journal.
(wilfyarkoni2020increasedincidenceof pages 2-3): A. Wilf-Yarkoni, O. Elkayam, O. Elkayam, O. Aizenstein, Y. Oron, V. Furer, V. Furer, Dinah Zur, Dinah Zur, M. Goldstein, M. Goldstein, D. Barequet, D. Barequet, H. Hallevi, A. Karni, A. Karni, Z. Habot-Wilner, Z. Habot-Wilner, and K. Regev. Increased incidence of susac syndrome: a case series study. BMC Neurology, Sep 2020. URL: https://doi.org/10.1186/s12883-020-01892-0, doi:10.1186/s12883-020-01892-0. This article has 37 citations and is from a peer-reviewed journal.
(bose2023susacsyndromeneurological pages 6-8): Smriti Bose, Athanasios Papathanasiou, Sameep Karkhanis, Jason P. Appleton, Dominic King, Ruchika Batra, Susan P. Mollan, and Saiju Jacob. Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients). Journal of Neurology, 270:6193-6206, Aug 2023. URL: https://doi.org/10.1007/s00415-023-11891-z, doi:10.1007/s00415-023-11891-z. This article has 28 citations and is from a domain leading peer-reviewed journal.
(koncz2024theneurocognitiveand pages 1-2): Rebecca Koncz, Miranda J. Say, Andrew Gleason, and Todd A. Hardy. The neurocognitive and neuropsychiatric manifestations of susac syndrome: a brief review of the literature and future directions. Neurological Sciences, 45:5181-5187, Jul 2024. URL: https://doi.org/10.1007/s10072-024-07672-9, doi:10.1007/s10072-024-07672-9. This article has 2 citations and is from a peer-reviewed journal.
(bose2023susacsyndromeneurological pages 5-6): Smriti Bose, Athanasios Papathanasiou, Sameep Karkhanis, Jason P. Appleton, Dominic King, Ruchika Batra, Susan P. Mollan, and Saiju Jacob. Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients). Journal of Neurology, 270:6193-6206, Aug 2023. URL: https://doi.org/10.1007/s00415-023-11891-z, doi:10.1007/s00415-023-11891-z. This article has 28 citations and is from a domain leading peer-reviewed journal.
(jarius2014clinicalparaclinicaland pages 8-9): Sven Jarius, Ilka Kleffner, Jan M Dörr, Jaume Sastre-Garriga, Zsolt Illes, Eric Eggenberger, Colin Chalk, Marius Ringelstein, Orhan Aktas, Xavier Montalban, Kai Fechner, Winfried Stöcker, Erich B Ringelstein, Friedemann Paul, and Brigitte Wildemann. Clinical, paraclinical and serological findings in susac syndrome: an international multicenter study. Journal of Neuroinflammation, 11:46, Mar 2014. URL: https://doi.org/10.1186/1742-2094-11-46, doi:10.1186/1742-2094-11-46. This article has 165 citations and is from a peer-reviewed journal.
(cvikova2024casereportsusac pages 1-2): Martina Cviková, Jakub Štefela, Vít Všianský, Michal Dufek, Irena Doležalová, Jan Vinklárek, Roman Herzig, Markéta Zemanová, Vladimír Červeňák, Jaroslav Brichta, Veronika Bárková, David Kouřil, Petr Aulický, Pavel Filip, and Viktor Weiss. Case report: susac syndrome—two ends of the spectrum, single center case reports and review of the literature. Frontiers in Neurology, Feb 2024. URL: https://doi.org/10.3389/fneur.2024.1339438, doi:10.3389/fneur.2024.1339438. This article has 8 citations and is from a peer-reviewed journal.
(cvikova2024casereportsusac pages 7-8): Martina Cviková, Jakub Štefela, Vít Všianský, Michal Dufek, Irena Doležalová, Jan Vinklárek, Roman Herzig, Markéta Zemanová, Vladimír Červeňák, Jaroslav Brichta, Veronika Bárková, David Kouřil, Petr Aulický, Pavel Filip, and Viktor Weiss. Case report: susac syndrome—two ends of the spectrum, single center case reports and review of the literature. Frontiers in Neurology, Feb 2024. URL: https://doi.org/10.3389/fneur.2024.1339438, doi:10.3389/fneur.2024.1339438. This article has 8 citations and is from a peer-reviewed journal.
(bose2023susacsyndromeneurological pages 8-9): Smriti Bose, Athanasios Papathanasiou, Sameep Karkhanis, Jason P. Appleton, Dominic King, Ruchika Batra, Susan P. Mollan, and Saiju Jacob. Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients). Journal of Neurology, 270:6193-6206, Aug 2023. URL: https://doi.org/10.1007/s00415-023-11891-z, doi:10.1007/s00415-023-11891-z. This article has 28 citations and is from a domain leading peer-reviewed journal.
(vodopivec2016treatmentofsusac pages 1-3): Ivana Vodopivec and Sashank Prasad. Treatment of susac syndrome. Current Treatment Options in Neurology, 18:1-8, Dec 2016. URL: https://doi.org/10.1007/s11940-015-0386-x, doi:10.1007/s11940-015-0386-x. This article has 48 citations and is from a peer-reviewed journal.
(seifertheld2017susacssyndromeclinical pages 1-6): Thomas Seifert-Held, Beate J. Langner-Wegscheider, Martina Komposch, Philipp Simschitz, Claudia Franta, Barbara Teuchner, Hans Offenbacher, Ferdinand Otto, Johann Sellner, Helmut Rauschka, and Franz Fazekas. Susac's syndrome: clinical course and epidemiology in a central european population. International Journal of Neuroscience, 127:776-780, Sep 2017. URL: https://doi.org/10.1080/00207454.2016.1254631, doi:10.1080/00207454.2016.1254631. This article has 65 citations and is from a peer-reviewed journal.
(cvikova2024casereportsusac media 1cd8097f): Martina Cviková, Jakub Štefela, Vít Všianský, Michal Dufek, Irena Doležalová, Jan Vinklárek, Roman Herzig, Markéta Zemanová, Vladimír Červeňák, Jaroslav Brichta, Veronika Bárková, David Kouřil, Petr Aulický, Pavel Filip, and Viktor Weiss. Case report: susac syndrome—two ends of the spectrum, single center case reports and review of the literature. Frontiers in Neurology, Feb 2024. URL: https://doi.org/10.3389/fneur.2024.1339438, doi:10.3389/fneur.2024.1339438. This article has 8 citations and is from a peer-reviewed journal.
(NCT06881368 chunk 2): Phenotypic and Etiological Characterization of Susac Syndrome. Assistance Publique - Hôpitaux de Paris. 2025. ClinicalTrials.gov Identifier: NCT06881368
(cvikova2024casereportsusac media 4d784135): Martina Cviková, Jakub Štefela, Vít Všianský, Michal Dufek, Irena Doležalová, Jan Vinklárek, Roman Herzig, Markéta Zemanová, Vladimír Červeňák, Jaroslav Brichta, Veronika Bárková, David Kouřil, Petr Aulický, Pavel Filip, and Viktor Weiss. Case report: susac syndrome—two ends of the spectrum, single center case reports and review of the literature. Frontiers in Neurology, Feb 2024. URL: https://doi.org/10.3389/fneur.2024.1339438, doi:10.3389/fneur.2024.1339438. This article has 8 citations and is from a peer-reviewed journal.
(cvikova2024casereportsusac media bcac5361): Martina Cviková, Jakub Štefela, Vít Všianský, Michal Dufek, Irena Doležalová, Jan Vinklárek, Roman Herzig, Markéta Zemanová, Vladimír Červeňák, Jaroslav Brichta, Veronika Bárková, David Kouřil, Petr Aulický, Pavel Filip, and Viktor Weiss. Case report: susac syndrome—two ends of the spectrum, single center case reports and review of the literature. Frontiers in Neurology, Feb 2024. URL: https://doi.org/10.3389/fneur.2024.1339438, doi:10.3389/fneur.2024.1339438. This article has 8 citations and is from a peer-reviewed journal.
(cvikova2024casereportsusac media 5a95f86e): Martina Cviková, Jakub Štefela, Vít Všianský, Michal Dufek, Irena Doležalová, Jan Vinklárek, Roman Herzig, Markéta Zemanová, Vladimír Červeňák, Jaroslav Brichta, Veronika Bárková, David Kouřil, Petr Aulický, Pavel Filip, and Viktor Weiss. Case report: susac syndrome—two ends of the spectrum, single center case reports and review of the literature. Frontiers in Neurology, Feb 2024. URL: https://doi.org/10.3389/fneur.2024.1339438, doi:10.3389/fneur.2024.1339438. This article has 8 citations and is from a peer-reviewed journal.
(david2022susacsyndromea pages 4-5): Clémence David, Karim Sacré, Marie-Cécile Henri-Feugeas, Isabelle Klein, Serge Doan, Fleur Aubart Cohen, Eric Jouvent, and Thomas Papo. Susac syndrome: a scoping review. Autoimmunity Reviews, 21:103097, Jun 2022. URL: https://doi.org/10.1016/j.autrev.2022.103097, doi:10.1016/j.autrev.2022.103097. This article has 55 citations and is from a peer-reviewed journal.